Mablink Bioscience Announces A €31 Million Series A Funding Round Led By Sofinnova Partners And Mérieux Equity Partners
Amount Raised
€31 Million
Round Type
Series A
LyonBiotechnologyHealth CareTherapeuticsDescription
LYON, FRANCE / October 14, 2022 / Mablink Bioscience ("Mablink"), a biotechnology company aiming to transform cancer therapy using next-generation antibody-drug conjugates (ADCs), announced today that it has raised a €31 million Series A funding round to advance its lead candidate to the clinic and to build a pipeline of ADCs using its proprietary platform technology. The round was led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors.
Quick answer
Mablink Bioscience raised €31 Million in a Series A round, dated October 14, 2022. Mablink Bioscience is based in Lyon, Auvergne Rhône Alpes, France.
- How much did Mablink Bioscience raise?
- Mablink Bioscience raised €31 Million in a Series A round on October 14, 2022.
- What does Mablink Bioscience do?
- Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugate (ADC).
- Where is Mablink Bioscience based and how big is it?
- Mablink Bioscience is based in Lyon, Auvergne Rhône Alpes, France.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Mablink Bioscience that raised within 45 days of this round, from Fundz verified event records.
- Escient Pharmaceuticals raised $120M (Series C) on November 28, 2022.
- Parabilis Medicines raised $178M (Series D) on November 21, 2022.
- Opna Bio raised $38M (Series A) on November 21, 2022.
- Arialys Therapeutics raised $14M on November 18, 2022.
- Cue Biopharma raised an undisclosed amount (Funding Round) on November 17, 2022.
- Parabilis Medicines raised $178M on November 17, 2022.
Who to call at Mablink Bioscience, and when
A new round usually means Mablink Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Mablink Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Mablink Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Mablink Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Mablink Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansMablink Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.